Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 May 25;44(10):2113–2124. doi: 10.1038/s41401-023-01097-4

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s), under exclusive licence to Shanghai Institute of Materia Medica, Chinese Academy of Sciences and Chinese Pharmacological Society 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

PMC Copyright notice

Fig. 3 — a ChIP-qPCR verified the histone modification changes in the TfR-1 promoter region. b Venn diagram showing the differential expression of the statistically (P adjust < 0.05) enriched genes among the insensitive cell line U-2932 and the sensitive cell line Pfeiffer. GSEA analysis (using oncogenic c6 MSigDB gene set) of H3K27ac ChIP-seq data affected by EPZ-6438. The heatmap showing the enriched pathways (P adjust < 0.05) in the oncogenic signatures from the Molecular Signatures Database (MSigDB) with EPZ-6438 compared to DMSO treated U-2932 and Pfeiffer. The color was based on the enrichment score. c Oncogenic signature enrichment plots of H3K27ac ChIP-seq with EPZ-6438 treatment compared with DMSO treatment in U-2932. Plots indicate a significant (FDR q < 0.05) enrichment of oncogenic signatures after EPZ-6438 treatment. d, e c-Myc mRNA and protein levels were altered in cells treated with EPZ-6438 or HH2853 for 3 days. f DLBCL cells were transfected with lentivirus to deplete c-Myc expression. The indicated proteins in cells treated with or without 1 μM HH2853 were analyzed by immunoblotting (g). The histone modification changes in the MYC promoter region (h) and the c-Myc binding changes in the TFRC promoter region (i) were verified by ChIP-qPCR. The statistical analysis using Student’s t test with three biologic replicates, *P value < 0.05; **P value < 0.01, ***P value < 0.001.